HELLO! speaks to leading experts about the simple mistakes that can hold back results of weight loss injections or lead to unwanted side effects. See details.

Viking offers asymmetric upside in GLP-1 drugs with positive trial data, strong cash, and buyout potential despite biotech risks. Learn why VKTX stock is a strong buy.

Recent advancements in medical therapy for heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) include 3 classes of therapy—sodium glucose cotransporter ...

A team of researchers from the University of Minnesota Twin Cities College of Science and Engineering and the University of Houston's Cullen College of Engineering has discovered and measured the ...

Metsera's MET-097i cut weight up to 14% in Phase 2b trials, with manageable side effects, as the company targets a global Phase 3 program in 2025.

Vertanical’s cannabis-based pain reliever, VER-01, has shown superiority over opioids in a Phase III trial.

A team of researchers from the University of Minnesota Twin Cities College of Science and Engineering and the University of Houston’s Cullen College of Engineering has discovered and measured the ...

Once-daily INGREZZA treatment was generally well tolerated and showed early and sustained improvements in chorea severity Findings presented at 2025 MDS ...

A cannabis extract appears to provide sustained relief from chronic low back pain without signs of addiction or withdrawal, phase 3 data show.

One study examines the small molecular cardiac myosin inhibitor for safety and efficacy at 96 weeks, and another compares it to metoprolol for exercise performance.